Arthur Kuan serves as Chief Executive Officer of CG Oncology Inc., a late-stage clinical biopharmaceutical company dedicated to developing innovative therapies for bladder cancer. With over 25 years of experience in the biotechnology and pharmaceutical industries, Kuan has built a distinguished career focused on oncology drug development, strategic partnerships, and commercial execution. He joined CG Oncology in 2021, bringing deep expertise from prior leadership roles, including President and Chief Operating Officer at Agenus Inc., where he oversaw global clinical operations, regulatory affairs, and business development, successfully advancing multiple immunotherapy programs into late-stage trials. Prior to Agenus, Kuan held senior positions at Celgene Corporation, rising to Vice President of Business Development in Oncology, where he orchestrated high-value collaborations and acquisitions that expanded the company's immuno-oncology portfolio. His earlier career included key roles at Pfizer Inc. in global business development and alliance management, contributing to landmark deals exceeding $10 billion in value. Kuan's achievements include raising over $1 billion in financing across his tenure at various firms and navigating complex regulatory landscapes to achieve FDA approvals and breakthrough designations. At CG Oncology, Kuan leads the company's pivotal efforts around its lead candidate, cretostimogene grenadenorepvec (CG0070), an oncolytic immunotherapy currently under review for FDA approval as a potential first-line maintenance therapy for high-risk non-muscle invasive bladder cancer. Under his stewardship, the company has expanded its clinical footprint, forged strategic alliances, and positioned CG Oncology for potential commercialization, aiming to address significant unmet needs in urologic oncology.